Abstract: The present disclosure provides a process for preparing Bortezomib, intermediates, and crystalline forms thereof.

Abstract: The present disclosure provides a process for preparing Bortezomib, intermediates, and crystalline forms thereof.

Abstract: A filtrating module has a reservoir and a plurality of nozzles. The reservoir has an inlet opening, an outlet opening, a plurality of partitions, and a plurality of chambers. The chambers are respectively formed between each two adjacent ones of the partitions. Lower parts of the chambers communicate with each other but upper parts of the chambers are isolated from each other. The nozzles are respectively mounted under the inlet opening of the reservoir and in the upper parts of the chambers. Openings of the nozzles face downward and are inclined toward the next chamber, but the nozzle in the last chamber is inclined toward the outlet opening. A filtrating device includes the filtrating modules connected to each other. Therefore, the working fluid can be jetted downward and inclined to the liquid level of the working fluid, and thus contaminants in air can be dissolved in the working fluid.

Abstract: Disclosed is a 4,4?-dicarboxy-2,2?-bipyridine derived tridentate ligand represented by formula (I): wherein definitions of Y1, Y2, and R are the same as those defined in the specification. Also disclosed are a metal complex containing the aforesaid tridentate ligand and a dye-sensitized solar cell containing the metal complex.

Abstract: Disclosed is a 4,4?-dicarboxy-2,2?-bipyridine derived tridentate ligand represented by formula (I): wherein definitions of Y1, Y2, and R are the same as those defined in the specification. Also disclosed are a metal complex containing the aforesaid tridentate ligand and a dye-sensitized solar cell containing the metal complex.